A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

• Published in: Osteoarthritis and cartilage Vol. 25; no. 10; pp. 1598 - 1606
• Main Authors: Yazici, Y., McAlindon, T.E., Fleischmann, R., Gibofsky, A., Lane, N.E., Kivitz, A.J., Skrepnik, N., Armas, E., Swearingen, C.J., DiFrancesco, A., Tambiah, J.R.S., Hood, J., Hochberg, M.C.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.10.2017
• Subjects: Aged; Antirheumatic Agents - administration & dosage; Antirheumatic Agents - adverse effects; Antirheumatic Agents - pharmacokinetics; Antirheumatic Agents - therapeutic use; DMOAD; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles - administration & dosage; Imidazoles - adverse effects; Imidazoles - pharmacokinetics; Imidazoles - therapeutic use; Indazoles - administration & dosage; Indazoles - adverse effects; Indazoles - pharmacokinetics; Indazoles - therapeutic use; Injections, Intra-Articular; Male; Middle Aged; Osteoarthritis; Osteoarthritis, Knee - diagnostic imaging; Osteoarthritis, Knee - drug therapy; Pain Measurement - methods; Pyridines - administration & dosage; Pyridines - adverse effects; Pyridines - pharmacokinetics; Pyridines - therapeutic use; Radiography; Severity of Illness Index; Small molecule; Wnt pathway; Wnt Signaling Pathway - drug effects; Small molecule; DMOAD; Wnt pathway; Osteoarthritis

To assess the safety, pharmacokinetics, and exploratory efficacy of SM04690, a novel Wnt pathway inhibitor, as a potential disease modifying treatment for knee osteoarthritis (OA). Subjects with Kellgren-Lawrence grade 2–3 knee OA were randomized in successive dose-escalation cohorts to receive a kn...